Organization
Oncology Institute of Southern Switzerland
3 clinical trials
9 abstracts
Abstract
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.Org: Dana-Farber Cancer Institute, St. Luke’s Hospital, Division of Urology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Tor Vergata University of Rome,
Abstract
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.Org: Niguarda Cancer Center, Laboratory of Experimental Hematology, Clinic of Hematology, Ente Ospedaliero Cantonale, Universita’ della Svizzera italiana,
Abstract
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.Org: Oncology Institute of Southern Switzerland, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland, University of Southampton,
Clinical trial
Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2021-08-31
Clinical trial
Preoperative Treatment With Metronidazole to Evaluate the Efficacy in Reducing Fusobacterium Nucleatum Tumor Colonization in Patients With Colorectal Cancer (CRC): a Proof-of-concept TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced, Oligoprogressive NSCLC After Upfront Chemotherapy and Anti-PD1 Immunotherapy: A Multicentre, Single Arm, Phase II StudyStatus: Active (not recruiting), Estimated PCD: 2023-01-23
Abstract
Circulating tumor DNA of classical Hodgkin lymphoma.Org: Institute of Oncology Research, Aou Federico II, AO S.Croce e Carle, Clinical and Experimental Onco Hematology Unit, Medical University of Gdansk,
Abstract
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.Org: Swiss Group for Clinical Cancer Research (SAKK), Oncology Institute of Southern Switzerland, Pathology, Institute of Medical Genetics and Pathology,
Abstract
Breast cancer in patients with Lynch syndrome: A single institution retrospective analysis.Org: Azienda Ospedaliera Universitaria Senese, Ospedale Biella ASLBI, University of Siena, International Medical University in Rome Unicamillus, Ist Oncol Meidterraneo,
Abstract
Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.Org: Veracyte, Inc., Ghent University Hospital, Northwestern University Feinberg School of Medicine, Helen Diller Family Comprehensive Cancer Center, Oncology Institute of Southern Switzerland,
Abstract
Pelvic Ewing sarcoma in children: Multimodal treatment, long term outcome and prognostic factors.Org: Istanbul University School of Medicine, Oncology Institute of Southern Switzerland, Pediatric Hematology-Oncology, Radiation Oncology Division, Istanbul Medical Faculty,
Abstract
Integrating radiation therapy with CDK4/6 inhibitors for breast cancer: A systematic review and meta-analysis of toxicity.Org: Azienda Ospedaliera Universitaria Careggi, University of Florence, AOUC, CyberKnife Center, Istituto Fiorentino di Cura e Assistenza (IFCA), The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,